Biogen Idec’s ALS drug Failed Final Clinical Trial


Biogen Idec’s ALS drug Failed Final Clinical Trial

As per reports, it has been recently revealed that Biogen Idec was unable to get through the last clinical trial of its ALS drug. Researchers have acknowledged the loss by saying that it was not only shocking but discouraging as well.

Dr. Robert Brown, who is an ALS researcher, was of the view that they have worked hard on the drug, but they failed a crucial test. However, this does not mean that no more research will take as the disease needs an effective treatment.

While talking about the last and final clinical trial, which could not attain success, Brown said that they had enrolled 943 people, who were suffering from amyotrophic lateral sclerosis. They were enrolled to test the efficacy of their once-promising dexpramipexole drug.

After carrying out the study, Brown said that they did not find any sort of benefit from the drug. And, then only, they decided to halt the programme. "While these results were not what we expected, we hope this data will provide a foundation for future ALS research", said Dr. Douglas Kerr, who is the director of neurodegeneration clinical research at Biogen.

The failure does not mark an end to the research, said Kerr, as they still have been working on it.


Latest News

Sources Say ABInBev will Possibly Raise SABMiller Bid to Around 43 to 44 Pounds
William Lewis
Weaker Dollar and Lower U.S Rig Count Help Oil Edge Up
Gold Gains as Investors do not See any Chance of US Rate Hike Immediately
Contract Fees is the Key Reason for Tegna and Dish Spat
A Rise in the Medicare Premiums Could Mean Huge Increase for some and Opportunit
Organization for Economic Co-operation and Development
New Twitter CEO Expected to Cut Costs and Bring Changes
Deutsche Bank Q3 Loss may be a Record One in a Decade
Volkswagen Scandal Worries the City of Wolfsburg
Strong Component Sale and Weak Won help Samsung’s Third Quarter Profits
Is the U.S. Shale Oil Boom Heading Towards the Beginning of Its End?